Comparative Pharmacology
Head-to-head clinical analysis: LYGEN versus NATURAL ESTROGENIC SUBSTANCE ESTRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYGEN versus NATURAL ESTROGENIC SUBSTANCE ESTRONE.
LYGEN vs NATURAL ESTROGENIC SUBSTANCE-ESTRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lysergic acid diethylamide (LSD) acts as a partial agonist at serotonin 5-HT2A receptors in the brain, leading to altered glutamatergic signaling and neural network modulation.
Estrone binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent estrogenic effects on target tissues.
For adults, administer 500 mg orally twice daily with or without food.
0.1 to 0.5 mg intramuscularly 2 to 3 times per week for estrogen replacement therapy
None Documented
None Documented
12 hours; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min)
Terminal half-life: 24-48 hours (prolonged due to enterohepatic recirculation and tissue distribution).
Renal (90% as unchanged drug), biliary/fecal (10%)
Renal: ~50% (as glucuronide and sulfate conjugates), Biliary/Fecal: ~50% (enterohepatic recirculation).
Category C
Category C
Estrogen
Estrogen